The treatment of hypercholesterolemia is in a crossroad

Main Article Content

Arturo Zárate
<p>Unidad de Investigaci&oacute;n en Enfermedades Endocrinas, Diabetes y Metabolismo, Hospital de Especialidades, Centro M&eacute;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&eacute;xico</p>

Lourdes Basurto-Acevedo
<p>Unidad de Investigaci&oacute;n en Endocrinolog&iacute;a, Diabetes y Metabolismo, Centro M&eacute;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de&nbsp;M&eacute;xico</p>

Renata Saucedo
<p>Unidad de Investigaci&oacute;n en Enfermedades Endocrinas, Diabetes y Metabolismo, Hospital de Especialidades, Centro M&eacute;dico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Ciudad de M&eacute;xico</p>

Keywords

Cholesterol, hypercholesterolemia, Cardiovascular diseases, Hydroxymethylglutaryl-CoA reductase inhibitors

Abstract

In order to correct the high level of cholesterol in blood is necessary to improve the life style which includes proper nutrition and physical exercise, but frequently is added some medication. The initial medication that is used is a stantin which decreases total cholesterol and low density cholesterol associated with increment in high density cholesterol in order to prevent cardiovascular involvement. It is frequent the addition of other medicaments, such as niacin or ezetemiba to achieve a greater effect on cholesterol disorders. The effectively of anti-cholesterol elevation should be evaluated by the occurrence of cardiovascular events, instead of the improvement in biochemist markers.

Abstract 102 | PDF (Spanish) Downloads 71

References

Shanes JG, Minadeo KN, Moret A, Groner M, Tabaie SA. Statin therapy in heart failure: prognostic effects and potential mechanism. Am Heart J 2007;254:617-623.

 

Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N.  Association of hemoglobin A1c with cardiovascular disease and mortality in adults. Ann Intern Med 2004;141    (6):413-420.

 

Zárate A, Basurto L, Saucedo R.  Akira Endo descubridor de las estatinas recibe Premio Lasker por el beneficio sobre la enfermedad cardiovascular. Rev Med IMSS 2009; 47(2):119-120.

 

Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analyses of data from 90 056 participants in 14 randomised trials of statins. Lancet  2005; 366:1267-1278.

 

Davery SG, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992;304; 431-434.

 

Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin Endocrinol 2009;70:815-828.

 

Nicholls SJ, Brewer HB, Kastelin JP, Krueger KA, Wang MD, Shao M,et al. Effects of the CETP inhibitor eva-cetrapib administered  monotherapy or in combination with statins on HDL and LDL cholesterol. JAMA 2011;306: 2099-2109.

Article Sidebar

PDF (Spanish)
Issue
Vol. 50 No. 1 (2012): January-February
Section
Editorial

Authors retain their copyright and grant the Revista Médica del IMSS the right of first publication. Articles are distributed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows sharing as long as the author and the original source are properly credited.

How to Cite

1.
Zárate A, Basurto-Acevedo L, Saucedo R. The treatment of hypercholesterolemia is in a crossroad. Rev Med Inst Mex Seguro Soc [Internet]. 2017 Jan. 30 [cited 2025 Jul. 15];50(1):1-4. Available from: https://revistamedica.imss.gob.mx/index.php/revista_medica/article/view/1230